Should 54gene prioritize developing diagnostic tools or focus on drug discovery partnerships?

Introduction

The trade-off question at hand is whether 54gene should prioritize developing diagnostic tools or focus on drug discovery partnerships. This decision is crucial for 54gene's strategic direction and resource allocation. I'll analyze this trade-off by examining the company's current position, market opportunities, and potential impacts on various stakeholders.

Step 1

Clarifying Questions (3 minutes)

• Business Context: I'm thinking 54gene's current revenue model might influence this decision. Could you share more about the company's primary revenue streams and how they're balanced between diagnostics and drug discovery?

Why it matters: Helps understand financial motivations behind each option Expected answer: Revenue split between diagnostics and partnerships Impact on approach: Would prioritize the option with stronger revenue potential

• User Impact: Based on 54gene's focus on African genomics, I'm curious about the current user base. Can you provide insights into the demographics and needs of 54gene's primary users or partners?

Why it matters: Ensures alignment with user needs and market demand Expected answer: Mix of African healthcare providers, research institutions, and pharma companies Impact on approach: Would tailor solution to address specific user pain points

• Technical Feasibility: Considering the complexity of both options, I'm wondering about 54gene's current technical capabilities. What's the state of 54gene's infrastructure for diagnostics vs. drug discovery?

Why it matters: Determines the feasibility and time-to-market for each option Expected answer: Stronger capabilities in one area over the other Impact on approach: Would factor in development time and resource requirements

• Resource Allocation: Given that both options likely require significant investment, I'm curious about 54gene's current resource distribution. How are human and financial resources currently allocated between diagnostics and drug discovery efforts?

Why it matters: Helps understand the potential for scaling either option Expected answer: Current resource split and available budget for expansion Impact on approach: Would influence recommendation based on existing momentum and available resources

• Timeline and Market Pressure: Considering the fast-paced nature of the biotech industry, I'm thinking about external pressures. Are there any immediate market opportunities or competitive threats that might influence the urgency of this decision?

Why it matters: Helps prioritize short-term vs. long-term strategies Expected answer: Specific market trends or competitor actions Impact on approach: Would adjust timeline and risk assessment based on external factors